Dual-antibody combination therapy produces three to seven months of viral suppression without pills
Powerful new PrEP and treatment drug should be effective as a small weekly pill
Ibalizumab, active against highly resistant HIV, now approved in US
Long-acting injectable ARVs are convenient and private, study participants report
New 'mini-pillbox' device could deliver three HIV drugs in a single once-weekly dose
Long-acting monoclonal antibody effective against multidrug-resistant HIV
Long-acting NRTI shows promise for HIV treatment and PrEP
Long-acting cabotegravir + rilpivirine injection shows good results at 96 weeks
Several new candidates in HIV drug pipeline discussed at conference
